S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Viking Therapeutics Stock Forecast, Price & News

+0.06 (+2.21%)
(As of 06/29/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
760,053 shs
Average Volume
1.12 million shs
Market Capitalization
$214.33 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Stock Forecast (MarketRank)

Overall MarketRank

1.87 out of 5 stars

Medical Sector

723rd out of 1,432 stocks

Pharmaceutical Preparations Industry

349th out of 685 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
Viking Therapeutics logo

About Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

VKTX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$-54.99 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$2.58 per share


Free Float
Market Cap
$214.33 million

Viking Therapeutics Frequently Asked Questions

Should I buy or sell Viking Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Viking Therapeutics stock.
View analyst ratings for Viking Therapeutics
or view top-rated stocks.

What is Viking Therapeutics' stock price forecast for 2022?

5 Wall Street analysts have issued 1-year price objectives for Viking Therapeutics' shares. Their VKTX stock forecasts range from $10.00 to $15.00. On average, they predict Viking Therapeutics' stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 387.4% from the stock's current price.
View analysts' price targets for Viking Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Viking Therapeutics' stock price performed in 2022?

Viking Therapeutics' stock was trading at $4.60 at the beginning of the year. Since then, VKTX stock has decreased by 39.8% and is now trading at $2.77.
View the best growth stocks for 2022 here

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Viking Therapeutics

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) released its quarterly earnings results on Wednesday, April, 27th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. During the same period in the prior year, the business posted ($0.19) EPS.
View Viking Therapeutics' earnings history

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the following people:
  • Dr. Brian Lian Ph.D., Pres, CEO & Director (Age 56, Pay $872k)
  • Mr. Gregory S. Zante, Chief Financial Officer (Age 51, Pay $536k)
  • Ms. Marianne Mancini, Chief Operating Officer (Age 57, Pay $543k)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 57)

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $2.77.

How much money does Viking Therapeutics make?

Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $214.33 million. The biotechnology company earns $-54.99 million in net income (profit) each year or ($0.740010) on an earnings per share basis.

How many employees does Viking Therapeutics have?

Viking Therapeutics employs 17 workers across the globe.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for Viking Therapeutics is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at [email protected].

This page (NASDAQ:VKTX) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.